Use of Paclitaxel in ovarian cancer is justified
The congratulations offered by Dr Harding to those health authorities yet to make Paclitaxel available to their patients with ovarian cancer are misplaced. The evidence was summarised in Effective Health Care and is set out more fully in the research evidence volume of the Guidance on Commissioning Cancer Services - ...
You need to be a subscriber to read more
Subscribe for unlimited access
With a HSJ subscription you’ll unlock:
- All HSJ news by sector, topic & region
- Breaking News announcements
- App for mobile and offline reading
- Comment and Daily Insights newsletters
- Regional roundup newsletters
- 10 expert briefings every fortnight (Premium only)
- Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)
Already a subscriber? Sign into your account here